{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:53:51Z","timestamp":1780412031828,"version":"3.54.1"},"reference-count":19,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,12,6]],"date-time":"2006-12-06T00:00:00Z","timestamp":1165363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2007,1]]},"abstract":"<jats:sec><jats:title>Summary<\/jats:title><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>The onset of acid inhibition for proton pump inhibitors is slower than with H<jats:sub>2<\/jats:sub>RAs and generally considered to be at a steady\u2010state after 5\u2003days. Thus, little direct comparison data exists between H<jats:sub>2<\/jats:sub>RAs and proton pump inhibitors for gastric acid suppression on day 1 of therapy. Furthermore, the durability of their acid suppression has not been systematically compared.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To compare the effects of 20.6\u2003mg omeprazole magnesium o.m. (Ome\u2010Mg 20), famotidine 10\u2003mg b.d. (Fam 10) and famotidine 20\u2003mg b.d. (Fam 20) on intragastric pH on day 1 and throughout 14 days of dosing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The study was a randomized, double\u2010blind, three\u2010dosing regimens, three\u2010period crossover. Healthy adults with frequent heartburn (\u22652\u2003days\/week) underwent 24\u2010h gastric pH monitoring on days 0 (baseline), 1, 3, 7 and 14.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty\u2010one subjects were included in the per\u2010protocol analyses. On day 1, the mean percentage time pH\u2003&gt;\u20034 (pH4%) was higher for Ome\u2010Mg 20, 44.6%, than for Fam 10, 36.7% (<jats:italic>P<\/jats:italic>\u2003=\u20030.032), and not different from Fam 20, 46.9% (<jats:italic>P<\/jats:italic>\u2003=\u20030.541). The pH4% was higher for Ome\u2010Mg 20 than either famotidine regimen on all subsequent monitoring days (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001). The 24\u2010h area under the mean intragastric pH curve showed a similar pattern. Furthermore, after day 1, Ome\u2010Mg 20 demonstrated an increasing and sustained effect in contrast to a decreasing effect for famotidine, consistent with H<jats:sub>2<\/jats:sub>RA tolerance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Gastric acid suppression on Ome\u2010Mg 20 mg o.m. over 14\u2003days was comparable with Fam 10\u2003mg b.d. or Fam 20 mg b.d. on day 1, and superior thereafter.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2006.03129.x","type":"journal-article","created":{"date-parts":[[2010,7,23]],"date-time":"2010-07-23T12:40:32Z","timestamp":1279888832000},"page":"103-109","source":"Crossref","is-referenced-by-count":51,"title":["Comparison of gastric pH with omeprazole magnesium 20.6\u2003mg (Prilosec OTC) o.m. famotidine 10\u2003mg (Pepcid AC) b.d. and famotidine 20\u2003mg b.d. over 14\u2003days of treatment"],"prefix":"10.1111","volume":"25","author":[{"suffix":"JR","given":"P. B.","family":"MINER","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. D.","family":"ALLGOOD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"GRENDER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,12,6]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.08783.x"},{"key":"e_1_2_6_3_2","first-page":"17S","article-title":"Optimizing the pharmacology of acid control in acid\u2010related disorder","volume":"92","author":"Howden CW","year":"1997","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"e_1_2_6_4_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2036.1993.tb00582.x","article-title":"The continuing development of gastric pump inhibitors","volume":"7","author":"Sachs G","year":"1993","journal-title":"Aliment Pharmacol Ther"},{"key":"e_1_2_6_5_2","first-page":"17S","article-title":"Optimizing the pharmacology of acid control in acid\u2010related disorder","volume":"92","author":"Howden CW","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02140.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000200917"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.7.649"},{"key":"e_1_2_6_9_2","first-page":"59","article-title":"Optimizing medical therapy for gastroesophageal reflux diseases: state of the art","volume":"3","author":"Katz PO","year":"2003","journal-title":"Rev Gastroenterol Disord"},{"key":"e_1_2_6_10_2","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/0016-5085(92)90025-T","article-title":"Effect of intravenous and oral dosing on 24\u2010hour intragastric acidity in duodenal ulcer patients","volume":"103","author":"Cederberg C","year":"1982","journal-title":"Gastroenterology"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.24.4.270"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1994.tb00278.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.01701.x"},{"issue":"1","key":"e_1_2_6_14_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2036.1990.tb00010.x","article-title":"Tolerance during 29\u2003days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine","volume":"4","author":"Nwokolo CU","year":"1990","journal-title":"Aliment Pharmacol Ther"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01537246"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.00198.x"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/j.1572-0241.1999.1123_a.x","article-title":"Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease","volume":"94","author":"DeVault KR","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.296.6615.89"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529709011211"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2004.00620.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2006.03129.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2006.03129.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T08:38:35Z","timestamp":1740299915000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2006.03129.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12,6]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["10.1111\/j.1365-2036.2006.03129.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2006.03129.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12,6]]}}}